Odisha News, Odisha Latest news, Odisha Daily - OrissaPOST
  • Home
  • State
  • Metro
  • National
  • International
  • Business
  • Opinion
  • Feature
  • Timeout
  • Entertainment
  • Sports
  • Sci-Tech
  • Others
    • COVID-19
    • Today’s Pic
  • Home
  • State
  • Metro
  • National
  • International
  • Business
  • Opinion
  • Feature
  • Timeout
  • Entertainment
  • Sports
  • Sci-Tech
  • Others
    • COVID-19
    • Today’s Pic
No Result
View All Result
OrissaPOST - Odisha Latest news, English Daily -
No Result
View All Result

Drug ‘Osimertinib’ provides new hope to lung cancer patients

PTI
Updated: June 8th, 2023, 07:20 IST
in International, Sci-Tech
0
Drug
Share on FacebookShare on TwitterShare on WhatsAppShare on Linkedin

New Delhi: A once-daily pill halved people’s risk of dying from a common lung cancer when they took the drug after tumour-removal surgery, trial results from a global study has proved. The research has been published recently in ‘The New England Journal of Medicine’. It states that taking the drug ‘Osimertinib’ after surgery dramatically reduced the risk of patients dying by 51 per cent.

The researchers randomly assigned eligible patients in a 1:1 ratio to receive Osimertinib (80mg once daily) or placebo until disease recurrence was observed. Of 682 patients who underwent randomisation, 339 received ‘Osimertinib’ also known as ‘Tagrisso’ and made by AstraZeneca, and 343 received placebo.

In the primary analysis population, an estimated 85 per cent of patients treated with Osimertinib were alive at five years compared to 73 per cent on placebo, the researchers said. In the overall trial population, an estimated 88 per cent of patients treated with ‘Osimertinib’ were alive at five years compared to 78 per cent on placebo, they said.

The study found that ‘Osimertinib’ reduced the risk of death by 51 per cent compared to placebo in both the primary analysis population, the researchers said.

“These highly anticipated overall survival results, with 88 per cent of patients alive at five years, are a momentous achievement in the treatment of early-stage EGFR-mutated lung cancer,” said principal investigator in the trial, Roy S Herbst, Deputy Director and Chief of Medical Oncology at Yale Cancer Centre and Smilow Cancer Hospital, US. “These data underscore that adjuvant treatment with ‘Osimertinib’ provides patients with the best chance of long-term survival,” Herbst said.

Susan Galbraith, executive vice-president, Oncology R&D, AstraZeneca, said ‘Osimertinib’ cut the risk of death by more than half in the adjuvant setting, further establishing this transformative medicine as the backbone treatment for epidermal growth factor receptor (EGFR)-mutated lung cancer.

“These results emphasise the importance of diagnosing patients with lung cancer early, testing for EGFR mutations and treating all those with an EGFR mutation with Tagrisso (Osimertinib),” Galbraith said.

The trial results were presented Monday during the Plenary Session at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago

 

Tags: AstraZenecacancerdeathdruglungOsimertinib
ShareTweetSendShare
Suggest A Correction

Enter your email to get our daily news in your inbox.

Related Posts

Akshata Murty - Rishi Sunak

Akshata Murty makes UK political stage debut for ‘best friend’ UK PM Rishi Sunak

October 4, 2023
Mohamed Muizzu (AFP)

Indian envoy meets Maldives’ President-elect, hands over congratulatory message from PM Narendra Modi

October 4, 2023
Elon Musk

Elon Musk tops Forbes’ 400 richest people in US, Bezos ranks second

October 4, 2023
Image used for representational purpose only | AP

Greece wants European Union to sanction countries that refuse deported migrants, minister says

October 4, 2023
Pic- africadailynews.com

More than 500 migrants arrive on Spanish Canary Islands in one day

October 4, 2023
Pakistan PM picks Lt Gen Asim Munir as new army chief

US defence secretary speaks with Pak Army chief amidst spike in terror attacks in Pakistan

October 4, 2023

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

OrissaPOST epaper Sunday POST OrissaPOST epaper

Click Here: Plastic Free Odisha

No Content Available

Archives

Editorial

Proxy War 

Mohamed Muizzu (AFP)
October 4, 2023

Bad news comes for India from Maldives. The Indian Ocean archipelago occupies a crucial position in the geopolitics of the...

Read more

Peso Vs Dollar

October 3, 2023

The ‘pink tide’ that swept across much of Latin America in the past few months installing Leftist governments in Brazil,...

Read more

‘Scandals’ In China

October 2, 2023

Something is seriously wrong in China. Even as it goes on testing India’s military mettle and teasing the political leadership...

Read more

Discrimination

October 1, 2023

Four centuries ago, the ambassador Sir Henry Wotton defined a diplomat as “an honest gentleman sent to lie abroad for...

Read more
  • Home
  • State
  • Metro
  • National
  • International
  • Business
  • Opinion
  • Feature
  • Sports
  • Sci-Tech
  • About Us
  • Advertise
  • Contact Us
  • Career
Developed By Ratna Technology

© 2020 All rights Reserved by OrissaPOST

  • Home
  • Metro
  • State
  • National
  • International
  • Sports
  • Business
  • Entertainment
  • Feature
  • Opinion
  • Sci-Tech
  • COVID-19
  • Today’s Pic
  • About Us
  • Contact Us
  • Career
  • Facebook
  • Twitter

© 2020 All rights Reserved by OrissaPOST